Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Pharmacoeconomics. 2018 Dec;36(12):1427-1437. doi: 10.1007/s40273-018-0677-7
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Pharmacoeconomics. 2018 Dec;36(12):1427-1437. doi: 10.1007/s40273-018-0677-7
Lancet 2018;391:2513–24
Rheumatol Ther. 2018 Dec;5(2):341-353. doi: 10.1007/s40744-018-0113-7
Clin Pharmacol Drug Dev. 2019 Feb;8(2):208-216. doi: 10.1002/cpdd.462
Drug Saf 2018 Apr; 41(4):357–61 DOI: 10.1007/s40264-017-0622-2
Pharmacoeconomics 2018 Jul; 36(7):769–78
Pharmacoeconomics 2018 Sep; 36(9): 1063–72
Arthritis Res Ther 2018; 20(1):60 doi: 10.1186/s13075-018-1539-6
Arthritis Res Ther 2018; 20(1):57 doi: 10.1186/s13075-018-1541-z